Z Liu1,2, Q Fang1,2, J Zuo1,2, V Minhas3, C Wood3, T Zhang1,2. 1. Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China. 2. Key Laboratory of Public Health Safety (Fudan University), Ministry of Education, Shanghai, China. 3. Nebraska Center of Virology and the School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA.
Abstract
OBJECTIVES: Kaposi's sarcoma (KS) is a multicentric angioproliferative cancer of endothelial origin typically occurring in the context of immunosuppression or immunodeficiency. Consequently, KS is one of the most common cancers in HIV-infected individuals and frequently occurs among transplant recipients. Nevertheless, its incidence in different populations is not well understood. METHODS: We searched online databases for publications on KS incidence. A random-effect meta-analysis was performed to combine the KS incidences and incidence rate ratios (IRRs) for associated risk factors. RESULTS: Seventy-six eligible studies representing 71 time periods were included. For HIV-infected people, the overall KS incidence was 481.54 per 100 000 person-years with a 95% confidential interval (CI) of 342.36-677.32 per 100 000 person-years. HIV-infected men who have sex with men (MSM) had the highest incidence of KS (1397.11 per 100 000 person-years; 95% CI 870.55-2242.18 per 100 000 person-years). The incidence of KS was significantly lower in female than in male individuals (IRR 3.09; 95% CI 1.70-5.62). People receiving highly active antiretroviral therapy (HAART) had a lower incidence compared with people who had never received HAART (IRR 6.57; 95% CI 1.91-24.69). The incidence of KS was 68.59 (95% CI 31.39-149.86) per 100 000 person-years in transplant recipients, 52.94 (95% CI 39.90-70.20) per 100 000 person-years in children with HIV infection, and 1.53 (95% CI 0.33-7.08) per 100 000 person-years in the general population. CONCLUSIONS: Globally, a relatively high incidence of KS was found among HIV-seropositive people and, in particular, in HIV-infected MSM. The introduction of HAART has largely prevented the development of KS, but it has not entirely removed the challenge of KS. In Africa, in particular, KS imposes a very heavy disease burden, which can mainly be attributed to the high prevalence of KS-associated herpesvirus and poor access to HAART.
OBJECTIVES:Kaposi's sarcoma (KS) is a multicentric angioproliferative cancer of endothelial origin typically occurring in the context of immunosuppression or immunodeficiency. Consequently, KS is one of the most common cancers in HIV-infected individuals and frequently occurs among transplant recipients. Nevertheless, its incidence in different populations is not well understood. METHODS: We searched online databases for publications on KS incidence. A random-effect meta-analysis was performed to combine the KS incidences and incidence rate ratios (IRRs) for associated risk factors. RESULTS: Seventy-six eligible studies representing 71 time periods were included. For HIV-infected people, the overall KS incidence was 481.54 per 100 000 person-years with a 95% confidential interval (CI) of 342.36-677.32 per 100 000 person-years. HIV-infectedmen who have sex with men (MSM) had the highest incidence of KS (1397.11 per 100 000 person-years; 95% CI 870.55-2242.18 per 100 000 person-years). The incidence of KS was significantly lower in female than in male individuals (IRR 3.09; 95% CI 1.70-5.62). People receiving highly active antiretroviral therapy (HAART) had a lower incidence compared with people who had never received HAART (IRR 6.57; 95% CI 1.91-24.69). The incidence of KS was 68.59 (95% CI 31.39-149.86) per 100 000 person-years in transplant recipients, 52.94 (95% CI 39.90-70.20) per 100 000 person-years in children with HIV infection, and 1.53 (95% CI 0.33-7.08) per 100 000 person-years in the general population. CONCLUSIONS: Globally, a relatively high incidence of KS was found among HIV-seropositive people and, in particular, in HIV-infected MSM. The introduction of HAART has largely prevented the development of KS, but it has not entirely removed the challenge of KS. In Africa, in particular, KS imposes a very heavy disease burden, which can mainly be attributed to the high prevalence of KS-associated herpesvirus and poor access to HAART.
Authors: Kelsey Yetsko; Jessica A Farrell; Nicholas B Blackburn; Liam Whitmore; Maximilian R Stammnitz; Jenny Whilde; Catherine B Eastman; Devon Rollinson Ramia; Rachel Thomas; Aleksandar Krstic; Paul Linser; Simon Creer; Gary Carvalho; Mariana A Devlin; Nina Nahvi; Ana Cristina Leandro; Thomas W deMaar; Brooke Burkhalter; Elizabeth P Murchison; Christine Schnitzler; David J Duffy Journal: Commun Biol Date: 2021-02-01
Authors: Jessica L Castilho; Ahra Kim; Cathy A Jenkins; Beatriz Grinsztejn; Eduardo Gotuzzo; Valeria Fink; Denis Padgett; Pablo F Belaunzaran-Zamudio; Brenda Crabtree-Ramírez; Maria Mercedes Escuder; Rosa Alencar Souza; Simone B Tenore; Sidnei R Pimentel; Maria Letícia Rodrigues Ikeda; Paulo R de Alencastro; Unai Tupinanbas; Carlos Brites; Estela Luz; Juliana Netto; Claudia P Cortes; Alexandre Grangeiro; Bryan E Shepherd; Catherine C McGowan Journal: J Int AIDS Soc Date: 2021-01 Impact factor: 6.707